RxDoctor Payments Data

Mark Benfield

Pediatric Nephrology · Cullman, ALNPI 1811004245

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $195,295 of the $234,409 with a category attached, or 83.3%. Amgen accounts for 96.8% of it on its own, with 4 other manufacturers making up the rest.

$234,409in general payments, 2019–2025

Across 208 payments — averaging $1126.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$227K
  • Mallinckrodt Enterprises LLC$7K
  • Leadiant Biosciences, Inc.$212
  • Azurity Pharmaceuticals, Inc.$24
  • Travere Therapeutics, Inc.$15
$213,750in research payments, 2019–2025

Across 1 payment — averaging $213,750 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Mallinckrodt Hospital Products Inc.$214K

What the payments were for

  • Consulting fees$13,6976%
  • Speaking & faculty fees$195,29583%
  • Travel & lodging$22,44610%
  • Food & beverage$2,9571%
  • Education$150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric nephrology providers in Alabamato place this figure against a meaningful peer group, so we don't.

Other pediatric nephrology in Cullman

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →